Assessment of Therapeutic Tumor Response Using &lt;SUP&gt;99m&lt;/SUP&gt;Tc-Ethylenedicysteine-Glucosamine

Yang, David J.; Yukihiro, Masashi; Yu, Dongfang; Ito, Megumi; Oh, Chang-Sok; Kohanim, Saady; Azhdarinia, Ali; Kim, Chang-Guhn; Bryant, Jerry; Kim, E. Edmund; Podoloff, Donald A.

doi:10.1089/1084978041979625

Cited by 17 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Îïóõîëè íèç-êîé ñòåïåíè çëîêà÷åñòâåííîñòè (low-grade) õàðàêòåðèçî-âàëèñü ïîíèaeåííûì ìåòàáîëèçìîì ãëþêîçû, à îïóõîëè âûñîêîé ñòåïåíè çëîêà÷åñòâåííîñòè (high grade) -ãè-ïåðìåòàáîëèçìîì [55]. Ñêîðîñòü ãëèêîëèçà â ãëèîìàõ, îïðåäåëÿåìàÿ ìåòîäîì ÏÝÒ ñ 18 F-ÔÄÃ, áîëåå òî÷íî îòðà-aeàåò ñòåïåíü çëîêà÷åñòâåííîñòè, ÷åì äàííûå ÌÐÒ èëè ÊÒ [93].…”

Section: âîçìîAeíîñòè ïýò ñ [unclassified

<sup>18</sup>F-ФДГ и другие меченые производные глюкозы для использования в радионуклидной диагностике онкологических заболеваний (обзор)

Петриев¹,

Tishchenko²,

Красикова³

2016

Хим.-фарм. ж.

View full text Add to dashboard Cite

Ðàííÿÿ äèàãíîñòèêà çëîêà÷åñòâåííûõ îïóõîëåâûõ çà-áîëåâàíèé èãðàåò îïðåäåëÿþùóþ ðîëü ïðè âûáîðå òàê-òèêè ëå÷åíèÿ è ïðîãíîçå âûaeèâàåìîñòè îíêîëîãè÷åñêèõ áîëüíûõ. Äëÿ ðåøåíèÿ ýòîé çàäà÷è øèðîêî èñïîëüçóþòñÿ ìåòîäû ðàäèîíóêëèäíîé äèàãíîñòèêè (ÿäåðíîé ìåäèöè-íû) -ïëàíàðíàÿ ñöèíòèãðàôèÿ (ÏÑ), îäíîôîòîííàÿ ýìèññèîííàÿ êîìïüþòåðíàÿ òîìîãðàôèÿ (ÎÔÝÊÒ) è ïî-çèòðîííàÿ ýìèññèîííàÿ òîìîãðàôèÿ (ÏÝÒ). Ýòè ìåòîäû îñíîâàíû íà in vivo èçó÷åíèè ðàñïðåäåëåíèÿ ñîåäèíåíèé, ìå÷åííûõ ðàäèîàêòèâíûìè èçîòîïàìè (ðàäèîòðåéñåðîâ, ðàäèîôàðìïðåïàðàòîâ (ÐÔÏ)), ñ ïîìîùüþ âíåøíåé ñèñ-òåìû äåòåêòîðîâ; îíè ðàçëè÷àþòñÿ òèïîì è ÿäåðíî-ôèçè-÷åñêèìè õàðàêòåðèñòèêàìè èñïîëüçóåìûõ ðàäèîíóêëè-äîâ, ñïîñîáîì ðåãèñòðàöèè èõ èçëó÷åíèÿ è îáðàáîòêè äàííûõ, à òàêaeå íàáîðîì äîñòóïíûõ ðàäèîòðåéñåðîâ [1]. Ýòî äàåò âîçìîaeíîñòü ïîëó÷àòü èíôîðìàöèþ î íàðóøå-íèÿõ ôèçèîëîãè÷åñêèõ è áèîõèìè÷åñêèõ ïðîöåññîâ íà ìîëåêóëÿðíîì óðîâíå è âûÿâëÿòü ôóíêöèîíàëüíûå èçìå-íåíèÿ â îðãàíàõ è òêàíÿõ äî ïîÿâëåíèÿ êëèíè÷åñêèõ ïðè-çíàêîâ çàáîëåâàíèé. Â íàñòîÿùåå âðåìÿ ìåòîäû ÎÔÝÊÒ è ÏÝÒ ïðèìåíÿþòñÿ â ñî÷åòàíèè ñ àíàòîìî-òîïîãðàôè÷å-ñêèìè ìåòîäàìè ëó÷åâîé äèàãíîñòèêè, òàêèìè êàê êîì-ïüþòåðíàÿ ðåíòãåíîâñêàÿ òîìîãðàôèÿ (ÊÒ) è ìàãíèò-íî-ðåçîíàíñíàÿ òîìîãðàôèÿ (ÌÐÒ). Ïîñëåäíèå îòëè÷à-þòñÿ âûñîêîé ðàçðåøàþùåé ñïîñîáíîñòüþ è ÷åòêî âè-çóàëèçèðóþò ìîðôîëîãè÷åñêèå èçìåíåíèÿ îðãàíîâ è òêàíåé, ñòðóêòóðó è ðàçìåðû îïóõîëåâîãî íîâîîáðàçîâà-íèÿ, íî ïðè ýòîì íå äàþò èíôîðìàöèè î ôóíêöèîíàëü-íûõ èçìåíåíèÿõ, íàðóøåíèÿõ ìåòàáîëèçìà è äðóãèõ ïðî-öåññîâ, õàðàêòåðíûõ äëÿ çëîêà÷åñòâåííûõ êëåòîê. Ðàçðàáîòêè ãèáðèäíîé (ìóëüòèìîäàëüíîé) òåõíîëîãèè, ñîâìåùàþùåé ÏÝÒ è ÊÒ, ñîâìåùåíû â åäèíîì ÏÝÒ-ÊÒ ñêàíåðå, ñóùåñòâåííî ðàñøèðèëè âîçìîaeíîñòè îíêîäè-àãíîñòèêè [2].Ìóëüòèìîäàëüíûå òåõíîëîãèè èñïîëüçóþòñÿ è â ÎÔÝÊÒ, îäíàêî, ÏÝÒ ïðåâîñõîäèò ÎÔÝÊÒ ïî ÷óâñòâè-òåëüíîñòè, ðàçðåøàþùåé ñïîñîáíîñòè è äðóãèì õàðàêòå-ðèñòèêàì [3]. Èñïîëüçîâàíèå â ÏÝÒ êîðîòêîaeèâóùèõ öèêëîòðîííûõ ðàäèîíóêëèäîâ îáåñïå÷èâàåò óíèêàëüíûå âîçìîaeíîñòè ìåòîäà: ïîçèòðîííûé ðàñïàä ñîïðîâîaeäà-åòñÿ îáðàçîâàíèåì 2 âûñîêîýíåðãåòè÷íûõ ãàììà-êâàíòîâ àííèãèëÿöèè (0,511 ÌýÂ), èñïóñêàåìûõ ïîä óãëîì 180°, êîòîðûå ëåãêî äåòåêòèðóþòñÿ âíåøíåé ñèñòåìîé äåòåê-òîðîâ, îáúåäèíåííûõ â ñõåìó ñîâïàäåíèé, áåç èñïîëüçî-âàíèÿ ñâèíöîâûõ êîëëèìàòîðîâ. Áåçóñëîâíûì ïðåèìó-ùåñòâîì ÏÝÒ ÿâëÿåòñÿ òî, ÷òî íàèáîëåå êîðîòêîaeèâóùèå ÏÝÒ ðàäèîíóêëèäû (

show abstract

Section: âîçìîAeíîñòè ïýò ñ [unclassified

<sup>18</sup>F-ФДГ и другие меченые производные глюкозы для использования в радионуклидной диагностике онкологических заболеваний (обзор)

Петриев¹,

Tishchenko²,

Красикова³

2016

Хим.-фарм. ж.

View full text Add to dashboard Cite

show abstract

“…Our previous work demonstrated that tumor uptake of 99m Tc-EC-DG is via a glucose-mediated process [16,70]. One reason may be that the molecule (EC-DG) has multiple key structural position(s), such as positions 2 and 6 for Dglucosamine and the two COO-arms and two thiol (SH) locations for EC.…”

Section: Assessment Of Metabolic Imagingmentioning

confidence: 99%

Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals

Yang¹,

Azhdarinia²,

Kim³

2005

CMIR

Self Cite

View full text Add to dashboard Cite

Improvement of scintigraphic tumor imaging is extensively determined by the development of more tumor specific radiopharmaceuticals. Thus, to improve the differential diagnosis, prognosis, planning and monitoring of cancer treatment, several functional pharmaceuticals have been developed. Application of molecular targets for cancer imaging, therapy and prevention using generator-produced isotopes are the major focus of ongoing research projects. Radionuclide imaging modalities (positron emission tomography, PET; single photon emission computed tomography, SPECT) are diagnostic cross-sectional imaging techniques that map the location and concentration of radionuclide-labeled radiotracers.99m Tc-and 68 Ga-labeled agents using ethylenedicysteine (EC) as a chelator were synthesized and their potential uses to assess tumor targets were evaluated.99m Tc (t 1/2 =6 hr, 140 keV) is used for SPECT and 68 Ga (t 1/2 =68 min, 511 keV) is for PET. Molecular targets labeled with Tc-99m and Ga-68 can be utilized for prediction of therapeutic response, monitoring tumor response to treatment and differential diagnosis. Molecular targets for oncological research in (1) cell apoptosis, (2) gene and nucleic acid-based approach, (3) angiogenesis (4) tumor hypoxia, and (5) metabolic imaging are discussed. Numerous imaging ligands in these categories have been developed and evaluated in animals and humans. Molecular targets were imaged and their potential to redirect optimal cancer diagnosis and therapeutics were demonstrated.

show abstract

“…This blockade in the pathway causes an inability for further metabolism and thus remains in the cell. (13,14) In this study, we introduce a novel Gd-based contrast agent for cancer cell imaging. Our study foucosed on the expolation of the glucose transport system in order to Incorporate Gd conjugated with glucose (Gd-DTPA-DG) into the cancer cells.…”

Section: Iintroductionmentioning

confidence: 99%

In Vitro and In Vivo Studies Glycosylated Gadolinum Nanomagnetic Particleas (GD-DTPA-DG) as New Potential Metabolic Contrast Agent in MMRI

Heydarnezhadi

Alam

Haghgoo³

et al. 2015

IFMBE Proceedings

View full text Add to dashboard Cite

Abstract-: Early cancer diagnosis using MRI imaging is of high global interest as a noninvasive and powerful modality in molecular Imaging. Therefore demand for new MRI contrast agents, with an enhanced sensitivity and advanced functionalities that improve the targeting to specific tissues or organs, is very high. in thise study, D-glucose amine was conjugated to a well-known chelator, diethylenetriamine penta-acetic acid (DTPA), then labeled with Gd to achieve Gd-DTPA-DG, Which is a metabolic contrast agent in mMRI. The contrast agent was synthesized and characterized physicochemical using different techniques including dynamic light scattering (DLS), high resolution transmission electron microscopy (HTEM) and inductively coupled plasma atomic emission spectroscopy (ICP-AES). Efficacy of the targeted contrast agent was assessed by measuring relaxation rate in vitro and tumor MR imaging were performed to determine signal intensity (SI) in vivo ( 0.1 mmol Gd/kg ) in female balb/c mice model.According to the results, the nano metabolic contrast agent penetrate into cells and accumulated in tumor, which cause improve the contrast of tumor tissue in comparison with magnevist. The results showed that the novel nano contrast agent could become useful tool in early detection of cancer.

show abstract

Assessment of Therapeutic Tumor Response Using <SUP>99m</SUP>Tc-Ethylenedicysteine-Glucosamine

Abstract: Purpose: The aim of this study was to evaluate 99m Tc-ethylenedicysteine-glucosamine (EC-DG)

Cited by 17 publications

References 6 publications

<sup>18</sup>F-ФДГ и другие меченые производные глюкозы для использования в радионуклидной диагностике онкологических заболеваний (обзор)

<sup>18</sup>F-ФДГ и другие меченые производные глюкозы для использования в радионуклидной диагностике онкологических заболеваний (обзор)

Tumor Specific Imaging Using Tc-99m and Ga-68 Labeled Radiopharmaceuticals

In Vitro and In Vivo Studies Glycosylated Gadolinum Nanomagnetic Particleas (GD-DTPA-DG) as New Potential Metabolic Contrast Agent in MMRI

Contact Info

Product

Resources

About